Adjuvant radiotherapy following radical prostatectomy for prostate cancer with high risk characteristics
The quality of evidence is downgraded by study limitations (selective outcome reporting).
A Cochrane review 1 included 3 studies with a total of 1815 patients, assessing the effect of adjuvant radiotherapy (RT) following radical prostatectomy (RP) in prostate cancer. Patients were at increased risk of relapse due to extension of disease to seminal vesicles, prostate capsule or surgical margins.
Adjuvant RT following RP did not affect overall survival (OS) at 5 years (RD (risk difference) 0.00; 95% CI -0.03 to 0.03), but improved survival at 10 years (RD -0.11; 95% CI -0.20 to -0.02). Adjuvant RT did not reduce metastatic disease at 5 years (RD -0.00; 95% CI -0.04 to 0.03), but reduced it at 10 years (RD -0.11; 95% CI -0.20 to -0.01). It improved local control at 5 and 10 years (RD -0.10; 95% CI -0.13 to -0.06 and RD -0.14; 95% CI -0.21 to -0.07, respectively), and biochemical progression-free survival at 5 years and 10 years (RD -0.16; 95% CI -0.21 to -0.11 and RD -0.29; 95% CI -0.39 to -0.19, respectively).
1. Daly T, Hickey BE, Lehman M et al. Adjuvant radiotherapy following radical prostatectomy for prostate cancer. Cochrane Database Syst Rev 2011;(12):CD007234. [PMID:22161411]
Copyright © 2021 Duodecim Medical Publications Limited.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Complete Product Information.